

NCCN Hodgkin Lymphoma V.1.2012 – Teleconference – 09/08/11

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
HODG-7 Internal request: Suggest adding a footnote to consider adding rituximab for patients with relapsed lymphocyte predominant Hodgkin lymphoma (LPHL).	For patients who received RT as primary therapy and now have a suspected relapse, the recommendation is to treat per advanced disease (HODG-7). Based upon the dated in the noted references, the panel consensus was to add a footnote to clarify that rituximab should be considered for patients with LPHL.	<p>Azim HA, Jr., Pruneri G, Cocorocchio E, et al. Rituximab in lymphocyte-predominant Hodgkin disease. <i>Oncology</i> 2009;76:26-29. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19033694.</p> <p>Fanale MA, Lai C-M, McLaughlin P, et al. Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP. <i>ASH Annual Meeting Abstracts</i> 2010;116:2812-</p> <p>Jackson C, Sirohi B, Cunningham D, et al. Lymphocyte-predominant Hodgkin lymphoma—clinical features and treatment outcomes from a 30-year experience. <i>Annals of Oncology</i> 2010;21:2061-2068. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20332141.</p>	18	0	0
HODG-10 Internal request: Suggest adding a footnote regarding the role of maintenance rituximab.	Based upon the dated in the noted references, the panel consensus was to add the following footnote, “In some patients treated with rituximab alone, maintenance rituximab may be considered for 2 years” for stages IB, IIB, III-IV	<p>Horning SJ, Bartlett NL, Breslin S, et al. Results of a prospective phase II Trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD) [abstract]. <i>Blood</i> 2007;110:Abstract 644. Available at: http://abstracts.hematologylibrary.org/cgi/content/abstract/110/11/644.</p>	18	0	0

NCCN Hodgkin Lymphoma V.1.2012 – Teleconference – 09/08/11

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
HODG-E 1 of 2 Internal request: Suggest adding a bullet to consider adding rituximab for patients with relapsed LPHL.	For patients who received chemotherapy ± RT as primary therapy and now have a suspected relapse, the recommendation is to treat per advanced disease (HODG-7). Based upon the dated in the noted references, the panel consensus was to add a bullet to clarify that rituximab should be considered for patients with LPHL.	<p>Azim HA, Jr., Pruneri G, Cocorocchio E, et al. Rituximab in lymphocyte-predominant Hodgkin disease. <i>Oncology</i> 2009;76:26-29. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19033694.</p> <p>Fanale MA, Lai C-M, McLaughlin P, et al. Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP. <i>ASH Annual Meeting Abstracts</i> 2010;116:2812-</p> <p>Jackson C, Sirohi B, Cunningham D, et al. Lymphocyte-predominant Hodgkin lymphoma—clinical features and treatment outcomes from a 30-year experience. <i>Annals of Oncology</i> 2010;21:2061-2068. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20332141.</p>	18	0	0
HODG-E 2 of 2 Internal request: Add bendamustine to the list of agents for second-line therapy.	Based upon the data in the noted reference, the panel consensus was to add bendamustine as a treatment option in second-line therapy for patients with progressive disease or patients who received chemotherapy ± RT as primary therapy and now have a suspected relapsed.	Moskowitz AJ, Hamlin PA, Jr., Gerecitano J, et al. Bendamustine Is Highly Active in Heavily Pre-Treated Relapsed and Refractory Hodgkin Lymphoma and Serves as a Bridge to Allogeneic Stem Cell Transplant. <i>ASH Annual Meeting Abstracts</i> 2009;114:720-. Available at: http://abstracts.hematologylibrary.org/cgi/content/abstract/ashmtg;114/22/720 .	18	0	0